Clinical Trials Logo
  1. Home
  2. Migraine Without Aura
  3. NCT05211154

Evaluation of the Efficacy of Diclofenac Potassium and Rimegepant for the Acute Treatment of Migraine — ATOM  

Migraine Without Aura Clinical Trial

Official title:
A Randomized, Parallel-Group, Single-Attack, Open-Label Study to Evaluate the Efficacy of Diclofenac Potassium and Rimegepant for the Acute Treatment of Migraine (ATOM)

Clinical Trial Summary

In a real-world population of adults with migraine, the investigators would like to investigate whether 50 mg diclofenac potassium is non-inferior to 75 mg rimegepant in terms of pain freedom at 2 hours after drug intake.

Clinical Trial Description

The study design is a randomized, open-label, parallel-group, single-attack study with 50 mg diclofenac potassium and 75 mg rimegepant. 645 patients with migraine with or without aura according to the third edition of the International Classification of Headache Disorders (ICHD-3) will be included. Each subject will randomly be allocated to one treatment, and given 42 days to treat a single qualifying migraine attack of moderate to severe intensity. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT05211154
Study type Interventional
Source Danish Headache Center
Contact Messoud Ashina, Prof.
Phone 004538633385
Email messoud.ashina@regionh.dk
Status Recruiting
Phase Phase 4
Start date May 5, 2022
Completion date December 2025
View Details
See also
  Status Clinical Trial Phase
Recruiting NCT02202486 - Investigation of the Blood-brain and Blood-dura Barrier Durin Migraine Attacks Using MRI N/A
Completed NCT01687660 - Acupuncture for Migraine Prophylaxis N/A
Completed NCT00363532 - Functional MRI (fMRI) in CGRP Induced Migraine N/A
Completed NCT00123201 - Study to Evaluate the Efficacy and Safety of Dronabinol Metered Dose Inhaler (MDI) in Acute Treatment of Migraine Headache Phase 2
Active, not recruiting NCT04406649 - A Study to Evaluate the Safety of STS101 in the Acute Treatment of Migraine Phase 3
Completed NCT03874832 - A Phase I Study to Study the PK and Safety of Single Doses of STS101, DHE Injection and Nasal Spray in Healthy Subjects Phase 1
Recruiting NCT05565001 - The Involvement of ATP Sensitive Potassium Channel in Migraine Aura and Migraine Pain. N/A
Not yet recruiting NCT05416476 - Anisodine Hydrobromide For The Preventive Treatment Of Episodic Migraine Phase 3
Completed NCT04533568 - Ibuprofen in Migraine Patients Phase 4
Completed NCT04636359 - Study the Effect of Acupuncture on Migraine Patient Without Aura Via Functional Magnetic Resonance Imaging. N/A
Completed NCT00534560 - Dose Ranging Study of the Efficacy and Tolerability of Tonabersat in the Prophylaxis of Migraine Headache Phase 2
Terminated NCT04936061 - Transnasal Cooling for Migraine N/A
Recruiting NCT05281770 - Monoclonal CGRP Antibodies for Migraine Prevention - a Nationwide Real Life Study
Completed NCT00380263 - PACAP38´s (Pituitary Adenylate Cyclase-Activating Polypeptide) Headache Inducing Characteristics and Effects on the Cerebral Blood Flow N/A
Completed NCT00334178 - Evaluation of the Efficacy and Safety of Laxymig® as Prophylactic Treatment in Patients With Migraine Phase 3
Completed NCT03472378 - Can DFN-15 Terminate Migraine With Allodynia? Phase 2
Recruiting NCT04157192 - Brain Connectome for Acupuncture-treated Migraine Patients N/A
Completed NCT01471990 - Effect of PACAP38/VIP on Migraineurs Measured by Magnetic Resonance N/A
Active, not recruiting NCT00285402 - Efficacy and Safety Clinical Trial of Intranasal AST-726 for the Prevention of Migraine Phase 2
Completed NCT02765581 - Efficacy Study of Acupuncture in the Prevention of Migraine Without Aura N/A